cervical cancer

Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.

The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.

The researchers found that changes in histone modification at HPV integration events were correlated with upregulation of nearby genes and endogenous retroviruses.

The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.

The test, which is used to screen for cervical cancer, was previously approved by the agency for use with the Cobas 4800 system.

Profiling microbial communities in cervicovaginal samples from women carrying high-risk HPV strains, researchers found possible markers of pre-cancer progression.

The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.